Literature DB >> 22129562

Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report.

Herng Nieng Chan1, A John Rush, Andrew A Nierenberg, Madhukar Trivedi, Stephen R Wisniewski, G K Balasubramani, Edward S Friedman, Bradley N Gaynes, Lori Davis, David Morris, Maurizio Fava.   

Abstract

The objective of this paper was to determine whether the presence of more vs. fewer anxious symptom features, at baseline, are associated with other clinical features and treatment outcomes in out-patients with major depressive disorder (MDD). This single-blind, randomized trial enrolled 665 MDD out-patients to compare the efficacy of two antidepressant medication combinations against escitalopram after 12-wk acute treatment and follow-up (total 28 wk). The sample was divided into those with greater (vs. fewer) anxiety features using the anxiety/somatization subscale of the baseline 17-item Hamilton Rating Scale for Depression. Baseline sociodemographic and clinical features, treatment features and outcomes compared these two groups. Overall, 74.7% of participants met the threshold for 'anxious features'. They were more likely to be female, have other concurrent anxiety disorders, more severe depression, more lethargic and melancholic features and poorer cognitive and physical functioning, quality of life and work and social adjustment. In acute treatment, participants with anxious features received comparatively higher doses of mirtazapine and venlafaxine and reported more side-effects. The groups with and without anxious features did not differ in treatment outcomes and side-effect burden. Despite being associated with a distinct clinical profile, baseline anxious features were not clinically useful in predicting acute treatment outcomes or differential treatment response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129562     DOI: 10.1017/S1461145711001660

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  7 in total

1.  Pharmacologic treatment of dimensional anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Erica M Richards; Carlos A Zarate
Journal:  Prim Care Companion CNS Disord       Date:  2014-05-29

Review 2.  Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.

Authors:  Bharathi S Gadad; Manish K Jha; Andrew Czysz; Jennifer L Furman; Taryn L Mayes; Michael P Emslie; Madhukar H Trivedi
Journal:  J Affect Disord       Date:  2017-07-05       Impact factor: 4.839

3.  Ziprasidone augmentation for anxious depression.

Authors:  Dawn F Ionescu; Richard C Shelton; Lee Baer; Kathryn H Meade; Michaela B Swee; Maurizio Fava; George I Papakostas
Journal:  Int Clin Psychopharmacol       Date:  2016-11       Impact factor: 1.659

4.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

5.  The Relationship Between Depression Symptoms and Anxiety Symptoms During Acute ECT for Patients With Major Depressive Disorder.

Authors:  Chun-Jen Huang; Ching-Hua Lin; Jyh-I Wu; Wei-Cheng Yang
Journal:  Int J Neuropsychopharmacol       Date:  2019-10-01       Impact factor: 5.176

6.  Risk Factors for Anxiety in Major Depressive Disorder Patients.

Authors:  Li-Min Xin; Lin Chen; Zhen-Peng Ji; Suo-Yuan Zhang; Jun Wang; Yan-Hong Liu; Da-Fang Chen; Fu-De Yang; Gang Wang; Yi-Ru Fang; Zheng Lu; Hai-Chen Yang; Jian Hu; Zhi-Yu Chen; Yi Huang; Jing Sun; Xiao-Ping Wang; Hui-Chun Li; Jin-Bei Zhang; Tian-Mei Si
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-12-31       Impact factor: 2.582

7.  Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.

Authors:  Taylor A Braund; Gabriel Tillman; Donna M Palmer; Evian Gordon; A John Rush; Anthony W F Harris
Journal:  Transl Psychiatry       Date:  2021-08-04       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.